First Interchangeable Biosimilar to Humira Gets FDA Approval
Ankylosing Spondylitis Arthritis/rheumatic Disorders Colorectal Disorders Crohn Disease Dermatological Disorders Gastroenterology General Musculoskeletal Disorders News Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Ulcerative Colitis

First Interchangeable Biosimilar to Humira Gets FDA Approval

The Food and Drug Administration has approved Cyltezo® (adalimumab-adbm) as the first interchangeable biosimilar to Humira® (adalimumab). Cyltezo, a tumor necrosis factor (TNF) blocker, is indicated to treat adults with rheumatoid arthritis, psoriatic arthritis, ankylosing…

FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
Arthritis/rheumatic Disorders Cardiovascular Disease General Musculoskeletal Disorders News Oncology Rheumatoid Arthritis Thromboembolic Disorders

FDA: New Warnings and Limitations Set for Certain JAK Inhibitors

The Food and Drug Administration (FDA) is requiring revisions to the Boxed Warning for Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release), Olumiant (baricitinib), and Rinvoq (upadacitinib) to include information about the risks of serious cardiovascular-related events,…